Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.46
+1.0%
$1.40
$1.05
$5.17
$157.55M0.381.20 million shs244,027 shs
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$38.00
$37.94
$2.61
$38.90
$1.77B4.41.98 million shsN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$0.87
-3.2%
$0.71
$0.28
$2.45
$315.22M1.136.84 million shs2.43 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$30.27
+8.1%
$23.60
$16.16
$30.44
$1.23B0.75214,555 shs309,913 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$8.68
-3.6%
$10.50
$8.58
$25.07
$746.91M0.71.84 million shs445,019 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-1.70%-5.56%+8.65%+20.42%
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00%0.00%0.00%0.00%0.00%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%+10.85%+18.18%+75.88%-45.51%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%+9.08%+16.24%+50.00%+66.11%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
0.00%+2.61%-18.99%-15.75%-55.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.5869 of 5 stars
3.62.00.00.02.51.70.6
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.4938 of 5 stars
3.23.00.00.01.42.50.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.6478 of 5 stars
0.82.02.51.12.93.32.5
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.1317 of 5 stars
3.51.00.04.41.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$9.71572.27% Upside
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00
N/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67302.93% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.67
Reduce$21.80-22.12% Downside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.90
Moderate Buy$35.80285.94% Upside

Current Analyst Ratings Breakdown

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/9/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M8.36N/AN/A$1.44 per share1.00
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$14.87M119.01N/AN/A$4.13 per share9.20
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.08M10.58N/AN/A$0.40 per share2.28
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.11$2.11 per share13.25$6.34 per share4.41
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M33.71N/AN/A$3.38 per share2.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7835.8913.330.472.68%30.51%6.89%8/27/2025 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
5/5/2025Q1 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.71%N/A61.54%N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/A
5.35
5.35
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
1.53
5.80
5.75
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
8746.57 millionN/AOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.05 million82.52 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.46 +0.02 (+1.04%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Five Prime Therapeutics stock logo

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.87 -0.03 (-3.22%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$30.27 +2.27 (+8.11%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$8.68 -0.33 (-3.61%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.